Promoting apoptosis of neutrophils and phagocytosis by macrophages: novel strategies in the resolution of inflammation by Martin, Katherine, et al.
Promoting apoptosis of neutrophils and phagocytosis by
macrophages: novel strategies in the resolution of
inflammation
Katherine Martin, Delphine Ohayon, Ve´ronique Witko-Sarsat
To cite this version:
Katherine Martin, Delphine Ohayon, Ve´ronique Witko-Sarsat. Promoting apoptosis of neu-
trophils and phagocytosis by macrophages: novel strategies in the resolution of inflam-
mation. Swiss Medical Weekly, EMH Swiss Medical Publishers, 2015, 145, pp.w14056.
<10.4414/smw.2015.14056>. <inserm-01123849>
HAL Id: inserm-01123849
http://www.hal.inserm.fr/inserm-01123849
Submitted on 5 Mar 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Review article: Medical intelligence | Published 21 February 2015, doi:10.4414/smw.2015.14056
Cite this as: Swiss Med Wkly. 2015;145:w14056
Promoting apoptosis of neutrophils and phagocytosis by
macrophages: novel strategies in the resolution of
inflammation
Katherine R. Martina,b,c,d, Delphine Ohayona,b,c,d and Véronique Witko-Sarsata,b,c,d
a INSERM U1016, Cochin Institute Paris, France
b Paris Descartes University, Paris, France
c CNRS-UMR 8104, Paris, France
d Centre of Excellence, LABEX Inflamex, University Paris Diderot, France
Summary
Acute inflammation is the body’s response to infection
or injury, characterised by the rapid infiltration of poly-
morphonuclear neutrophils to the site of injury followed by
monocytes, which differentiate locally into macrophages.
The latter are essential for the removal of effete neutrophils
and provided that the harmful agent is eliminated, removal
of neutrophils will lead to the resolution of inflammation.
Perturbations in this process result in the persistence of in-
flammation and close control of pathways associated with
resolution are necessary to avoid chronic inflammation,
autoimmunity, or both. As our understanding of these pro-
cesses increase, drugs able to trigger pro-resolution path-
ways may represent an effective strategy for treating chron-
ic inflammatory diseases.
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The resolution of inflammation: an
active process
Neutrophils play an essential role in the acute phase of in-
flammation, they are the most abundant leucocyte in the
blood and typically the first mobilised to the site of injury
or infection [1, 2]. They are essential in the clearance of
pathogens and function through a number of intra- and
extra-cellular mechanisms (refer to fig. 1 for a summary of
these actions). During inflammation, neutrophils are activ-
ated and mobilised by cytokines, growth factors and even
components of pathogens. Their importance in immune re-
sponses is highlighted by the fact that absence or decreased
neutrophil numbers results in immunodeficiencies [3]. In
addition to their capacity to eliminate pathogens, recent
research suggests that neutrophils also play a significant
role in the inflammatory process associated with cancers
through their ability to interact with the tumour microen-
vironment [4]. While neutrophils are necessary for mount-
ing an appropriate immune response to pathogens, injury
and even tumours, they also play a key role in the initi-
ation of various pathologies including chronic inflammat-
ory diseases and autoimmunity. In fact in some cases, an
exaggerated influx of neutrophils is more deleterious than
the infection or injury itself [2]. In various diseases in-
cluding rheumatoid arthritis, cardiac infarction, acute graft
rejection and acute respiratory distress syndrome, neutro-
phils are the most potent mediator of tissue damage and fa-
cilitate the inflammatory process. That being said, neutro-
phils are essential in the maintenance of homeostasis and
recent research suggests that they have an ability to in-
teract not only with other immune cells but also non-im-
mune cells (epithelial, endothelial or stromal cells) in dif-
ferent pathophysiological conditions to regulate biological
processes [5]. Indeed, neutrophils possess a wide variety
of mediators with microbicidal activity as well as mediat-
ors which contribute to resolution of inflammation [6]. For
example, neutrophils play an important anti-inflammatory
role during both acute and chronic microbial infections,
through the secretion of immunoregulatory cytokines such
Figure 1
A summary of the function of neutrophils during immune responses.
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as IL-10, IL-1 receptor antagonist and TGF-beta [7–10].
Radical oxygen species produced by the NADPH oxidase
system are not only essential for killing bacteria but also
appear to be pivotal in terminating the inflammatory pro-
cess. The importance of radical oxygen species (ROS) in
the resolution of inflammation is highlighted by the pres-
ence of granuloma in patients with chronic granulomatous
disease, a disease characterised by a genetic defect in one
component of the NADPH oxidase complex. This concept
is also illustrated in intestinal inflammation [11].
While neutrophils can be pro-resolving, too much of a good
thing is deleterious as neutrophils are also loaded with ex-
tremely powerful molecules. Therefore a key to mounting
an effective immune response while avoiding unnecessary
damage to surrounding tissue is by controlling neutrophil
activation and survival. Mechanisms used to control neut-
rophil survival and promote the resolution of inflamma-
tion will be the focus of this review as well as potential
therapeutic strategies aimed at exploiting the pro-resolving
power of apoptotic neutrophils for the treatment of chronic
inflammatory diseases.
The life and death of a neutrophil
Mechanisms of neutrophil apoptosis
The life span of a neutrophil must be tightly regulated, as
extended survival is essential for the effective elimination
of pathogens and cell death necessary to prevent the re-
lease of the highly cytotoxic contents of activated neutro-
phils and subsequent tissue damage. It is also a process that
may be induced, delayed or enhanced by the microorgan-
isms depending on their ability to evade host defences or to
be affected by the health status of the host [2]. A key fea-
ture in the regulation of neutrophil fate is their ability to un-
dergo spontaneous apoptosis through the up regulation of
death signalling and down regulation of survival signalling
[12]. There are many different mechanisms responsible for
the balance between neutrophil apoptosis and survival and
disruptions in these mechanisms has the potential to lead to
uncontrolled inflammation. In fact, there is now an estab-
lished field of research aimed at understanding the regula-
tion of neutrophil apoptosis and its potential as a target for
therapeutic intervention during the acute phases of inflam-
matory and infectious diseases [13–15].
Pro-apoptotic
One well-characterised mechanism involved in neutrophil
apoptosis is the caspase signalling pathway. Both intrinsic
pathways involving the mitochondria and extrinsic mech-
anisms involving death receptors are able to activate cas-
pases. Extrinsic death factors include FasL and TNF-alpha,
although it should be noted that while neutrophils do ex-
press both FasL and FasR, it does not appear to be the
principal pathway involved in neutrophil death as mice de-
ficient in both proteins display normal levels of apoptos-
is [16]. Intrinsic signal pathways include ROS and oxidat-
ive stress, Bcl-2 family members and cytochrome C [17,
18]. Interestingly, while neutrophils contain barely detect-
able levels of cytochrome c, the trace amounts of this pro-
tein found within the cytoplasm are still able to facilitate
apoptosis by promoting high levels of procaspase 9 and the
assembly of the Apaf-1 apoptosome [10]. Although less
characterised than caspases, lysosomal enzymes also pro-
mote apoptosis in neutrophils and triggering “lysosomal
cell death” [19].
We employed a proteomic approach to identify cytosolic
proteins cleaved or modified during neutrophil apoptosis.
This study identified a number of cytoskeleton-associated
proteins cleaved during apoptosis, including gelsolin,
moesin and coronin-1A. Coronin-1A is a protein associated
with phagosome formation and NADPH-oxidase compon-
ents and our results suggest it may inhibit neutrophil ap-
optosis. When coronin-1A is overexpressed in the myeloid
cell line PLB985, which can differentiate into neutrophils,
this protein affected the activity of NADPH oxidase and
was able to inhibit apoptosis in neutrophils. We have also
observed an increase in coronin-1A expression and as-
sociated decrease in apoptosis in cystic fibrosis patients
compared to healthy controls [20]. Others have found that
coronin-1A may also be involved in the survival of T
lymphocytes and mutation in this gene can participate in
the development of autoimmunity [21, 22]. Taken together,
these observations indicate that coronin-1A, a well-charac-
terised structural protein, has the unexpected ability to reg-
ulate neutrophil activation and apoptosis. Further studies
examining the expression of coronin1A and its role in ap-
optosis may provide an insight into inflammatory disease
and targeting this pathway may lead to novel therapeutics
for the treatment of chronic inflammation.
Pro-survival
In addition to pro-apoptotic signalling pathways regulating
neutrophil death, there are also a number of pro-survival
factors that can prolong the lifespan of neutrophils. Upon
migration to the site of inflammation, the lifespan of a neut-
rophil increases due to the presence of pro-survival cy-
tokines and chemokines such G-CSF and GM-CSF, which
are present in the inflammatory microenvironment [23].
Neutrophil survival also increases following the adhesion
of cells to the microvasculature. Indeed, IL-8 is a well-
characterised cytokine involved in neutrophil adhesion and
increases in this cytokine delays neutrophil apoptosis.
While the mechanisms responsible for this increased sur-
vival of neutrophils is poorly understood, it likely acts to
promote neutrophil function, facilitate the recruitment of
monocytes and differentiation of macrophages and ensures
a rapid and robust immune response.
There are a number of transcription factors important in
neutrophil survival including hypoxia-inducible factor
(HIF) and Forkhead box O3A (FOXO3A). HIF-1α
and HIF-2α are upregulated in response to hypoxia and
both enhance neutrophil survival while FOXO3A is able
to promote neutrophils survival by suppressing the tran-
scription of FasL [24–26]. Another protein known to be in-
volved in the balance between apoptosis and survival is the
Bcl-2 homolog Myeloid Cell Leukaemia 1 (Mcl-1). Stud-
ies have shown that continual expression of this normally
short-lived protein was able to delay neutrophil apoptosis
and mice deficient in Mcl-1 suffer from neutropenia due
to reduced neutrophil survival [27]. While the mechanisms
responsible for this increased survival are not fully under-
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stood, it appears to be a result of an interaction and inhibi-
tion of the pro-apoptotic proteins BIM and Bak [28].
Given that neutrophils are terminally differentiated and
have no proliferative capacity, it was assumed that they
would also lack cell-cycle regulatory proteins. This is not
the case, as an expression of a number of cell cycle proteins
including cyclin-dependent kinases (CDK) and proliferat-
ing cell nuclear antigen (PCNA) have been observed in
mature neutrophils. In fact an emerging concept in neut-
rophil apoptosis and resolution of inflammation is the in-
volvement of these proteins. For example, while the ex-
pression of survivin is generally restricted to proliferating
cells where it is able to control cell cycle, recent studies
have described the re-expression of this protein in neut-
rophils during inflammation and increased expression is
associated with improved neutrophil survival [29]. Other
studies have demonstrated that neutrophils contain func-
tionally active cyclin-dependent kinases (CDK) and inhibi-
tion of these kinases by roscovitin triggers apoptosis [13].
Proliferating cell nuclear antigen
(PCNA): novel anti-apoptotic role
promoting neutrophil survival and
chronic inflammation
Figure 2
Proliferating cell nuclear antigen (PCNA) is localised to the cytosol
of myeloid progenitors and possesses a proliferative capacity.
During the late phases of granulocytic differentiation, PCNA is
exported from the nucleus and become exclusively cytosolic. In
mature neutrophils, PCNA controls neutrophil survival through its
interaction with other cytosolic proteins, such as procaspases, to
prevent their activation. Upon apoptosis induced by death signals
or during the physiologic turnover of neutrophils and potentially
following the modification of a partner protein, PCNA is targeted to
the proteasome to induce neutrophil death. As a result, cytosolic
PCNA is considered to be a scaffolding protein capable of
controlling neutrophil survival.
Continuing this search for cell-cycle regulatory proteins
expressed in neutrophils, our group has identified an un-
expected anti-apoptotic role for PCNA. PCNA is a critical
factor in DNA synthesis and repair, initially characterised
as the auxiliary protein for DNA polymerases delta and
epsilon [30]. To date, most of the function attributed to
PCNA related to its nuclear localisation and ability to con-
trol cell proliferation. It is able to interact with a number
of proteins within the nucleus including various enzymes
and regulatory proteins like CDKs as well as CDK-inhib-
itor p21/waf1 [31]. As a result of the broad array of inter-
acting partners, PCNA can be described as a “cellular com-
municator”, capable of linking numerous important cellular
processes [32]. PCNA is also involved in other cellular pro-
cesses unrelated to replication, which include nucleotide-
excision repair, mismatch repair and cell cycle.
In addition to its role in the nucleus, we have demonstrated
that mature neutrophils express high levels of PCNA ex-
clusively within the cytosol (fig. 2). This cytosolic PCNA
is degraded by the proteasome during physiological, Fas-
or gliotoxin-induced apoptosis and was found to increase
following G-CSF-induced survival in vitro without tran-
scriptional regulation and in vivo in G-CSF-treated patients
[18]. In a mouse model of LPS-induced lung inflammation,
airway neutrophils displayed increased survival associated
with increased PCNA levels and its expression decreased
in apoptotic cells during the resolution phase. During in-
flammation in cystic fibrosis and vasculitis, isolated neut-
rophils exhibit a delay in apoptosis and have increased
levels of PCNA. This same observation was made in neut-
rophils isolated from the synovial fluid of rheumatoid arth-
ritis patients and again this correlated with increased neut-
rophil survival [33].
Given that PCNA has no intrinsic enzymatic activity, its
biological function relies on its ability to mediate the asso-
ciations between different interacting partners. Most PCNA
interactions occur at the interdomain-connecting loop. In
the cytosol of a neutrophil, PCNA is able to bind procas-
pase-3, 8, 9 and 10, which in turn precludes their activation
(fig. 2) [18]. Our group demonstrated that purified PCNA
protected procaspase-9 from cytochrome c-induced activ-
ation which in turn had a strong anti-apoptotic effect on
neutrophils. PCNA overexpression in DMF-differentiated
PLB985 also significantly decreased TRAIL- or gliotoxin-
induced apoptosis and when the interdomain-connecting
loop of PCNA was mutated, this anti-apoptotic effect was
abolished [34]. Another well-characterised binding partner
is the CDK inhibitor p21/waf1, which also binds PCNA
at the interdomain-connecting loop. A small peptide cor-
responding to the residues 141–160 of p21/waf1 known as
carboxyp21 was found to interfere with PCNA-protein in-
teractions and in turn had a strong antiproliferative effect
[31]. Treating neutrophils with carboxyp21 peptide
triggered PCNA degradation and apoptosis, while treat-
ment with a mutated version of this peptide incapable of
binding to PCNA, had no effect on apoptosis. Moreover,
carboxyp21 peptide significantly inhibited G-CSF–induced
neutrophil survival. We believe that PCNA is an important
mediator in the survival of mature neutrophils and that the
interdomain-connecting loop is essential for this function.
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Efferocytosis: macrophages eating
apoptotic neutrophils holds the key to
inflammation resolution
As discussed above neutrophil survival and apoptosis are
important in ensuring an appropriate immune response
while at the same time limiting the destructive capacity of
neutrophil on the surrounding tissue [35]. Another essential
step in this process is the subsequent recognition and elim-
ination of apoptotic neutrophils by phagocytic cells such
as macrophages, a process known as efferocytosis [36]. In
fact, this process is now viewed as being central to the suc-
cessful resolution of inflammation and the initiation of tis-
sue repair where dying neutrophils themselves actually ex-
ert an anti-inflammatory effect by modulating the response
of surrounding cells towards an anti-inflammatory pheno-
type (fig. 3) [37].
Phagocytic leucocytes, predominantly macrophages, not
only ingest and destroy invading pathogens, but are
charged with clearing dead and dying neutrophils. The pro-
cess of efferocytosis involves a number of steps, which ul-
timately result in the removal of apoptotic cells. When a
neutrophil undergoes apoptosis, it releases a “find me” sig-
nal that can be detected by a macrophage and attracts it to-
wards the site of the dying cell. “Find me” signals include
nucleotides (ATP, UTP), chemokines (CX3CL1) and lip-
id lysophosphytidlycholine (LPC). Once the macrophage
reaches the apoptotic neutrophil, it is able to detect an “eat
me” signal on the surface of the dying cells through recept-
ors which signal to the macrophage to engulf the target.
To date a number of “eat me” signals have been charac-
terised including the exposure of phosphatidylserine (Pt-
dSER), changes in charge and glycosation patterns on the
cell surface, changes in ICAM-1 epitopes and exposure of
calreticulin, an endoplasmic reticulum protein [38]. It is
worth nothing that apoptotic neutrophils can also express
“don’t eat me” signals on their surface, such as proteinase
3 or PAI-1, which delays their removal by macrophages
[39, 40]. Once the apoptotic neutrophil has been ingested,
Figure 3
During sterile inflammation, neutrophils first adhere to the
endothelium and undergo diapedesis. Following a gradient of
chemotactic compounds, they migrate to the site of inflammation
and become activated, where they secrete oxidant and release
proteinases. During the normal progression of inflammation,
neutrophils undergo apoptosis and express “eat-me-signals” which
are recognised by macrophages. These macrophages phagocytose
the apoptotic neutrophils and are reprogrammed towards an anti-
inflammatory and pro-resolving state. This figure demonstrated the
various steps in the neutrophil cycle, which may be targeted by an
anti-inflammatory intervention.
it is processed by the phagolysosomal pathway, which de-
grades and reprocesses the material of the apoptotic neut-
rophil [41].
Efferocytosis is not just important because it removed dy-
ing neutrophils before they cause unnecessary tissue dam-
age, these apoptotic neutrophils also act as a powerful anti-
inflammatory stimulus for other cells involved in the res-
olution of inflammation. When a macrophage engulfs an
apoptotic neutrophil, it results in the release mediators cap-
able of suppressing inflammation. Studies performed in
vitro and in vivo demonstrate that following efferocytosis,
macrophages produce high levels of IL-10, TGF-β and
PGE2 and secrete factors involved in tissue repair includ-
ing VEGF. At the same time, apoptotic neutrophils sup-
press the production of TLR-dependant cytokine including
IL-6, IL-8 and TNF by macrophages [36]. In essence, mac-
rophages in an activated state are switched to a pro-resolv-
ing phenotype that is able to facilitate the resolution of in-
flammation and promote tissue repair. Any defect in this
“eat me” process has the potential to perpetuate inflamma-
tion and may eventually lead to chronic inflammatory dis-
eases.
Harnessing pro-resolving pathways
for therapeutic purposes?
Treatment of inflammatory diseases today is largely based
on interrupting the synthesis or action of mediators that
drive the host response to infection and injury. In fact, non-
steroidal anti-inflammatories, steroids and antihistamines
were all developed on this basis. While small-molecule in-
hibitors have provided the main treatment for chronic in-
flammatory disease such as arthritis and asthma, they are
not without their shortcomings including undesirable side
effects and increased susceptibility to infection. An altern-
ative approach being explored for the development of nov-
el therapeutics is now looking towards endogenous medi-
ators and exploring mechanisms able to switch off acute
inflammation and bring about resolution. Research into ac-
tivating pro-resolving pathways will likely reveal new av-
enues for the management of inflammatory diseases in the
future [42].
One group of inflammatory disorders which may benefit
from promoting the resolution of inflammation are autoim-
mune diseases. One theory regarding the induction of
autoimmune diseases hypothesises is that they result from
a defect in apoptosis or removal of apoptotic cells. These
defects lead to the immune system being exposed to frag-
ments of the dying cell, which are able to induce a sus-
tained humoral response to protein found on those frag-
ments [43–45]. Given the reliance of a number of autoim-
mune diseases on neutrophils, promoting neutrophil apop-
tosis and the subsequent resolution of inflammation, rep-
resents an attractive therapeutic option that could ameli-
orate disease symptoms while leaving host defence intact
[46].
Neutrophils are believed to play a critical role in the patho-
genesis of autoimmune vasculitides including Granulo-
matosis with polyangiitis (GPA, formally known as Wegen-
er’s), Microscopic polyangiitis (MPA) and Churg-Strauss
syndrome (CSS) [47]. In these diseases, neutrophils are not
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only the target of the autoantibodies but also the effect-
or cell responsible for mediating damage to the endotheli-
um and potentiating inflammation [48]. The autoantibodies
found in these diseases, anti-neutrophil cytoplasmic an-
tibodies (ANCA), target two neutrophil granule proteins,
proteinase 3 (PR3) and myeloperoxidase (MPO). Anti-PR3
ANCAs are associated with GPA, a disease characterised
by granulomatous inflammation of the upper and/or lower
respiratory tract, while anti-MPO ANCAs are present in
patients with MPA, an idiopathic necrotising crescentic
glomerulonephritis, and less frequently in Churg-Strauss
syndrome, a small vessel vasculitis associated hyper-
eosinophilia and asthma.
A number of studies have found that patients with ANCA-
associated vasculitis (AAV) display a defect in neutrophil
apoptosis compared to healthy controls [49, 50]. Addition-
ally, apoptotic neutrophils expressing ANCA antigens on
their surface can be opsonised by ANCA which enhances
recognition and subsequent uptake by macrophage via Fc-
receptor interaction. This leads to an increased synthesis of
pro-inflammatory mediators such as IL-8 and IL-1 by mac-
rophages, which results in the recruitment of more neutro-
phils and enhances the progression of inflammation [51].
One treatment currently used in the management of these
diseases is endoxan, an immunosuppressive drug able to
trigger severe neutropenia [52]. While combinations of en-
doxan and corticosteroids are beneficial in reducing the
symptoms of AAV, they are often poorly tolerated and have
serious side effects including the development of second-
ary immunodeficiency. While these side effects are highly
undesirable, this drug demonstrates that reducing neutro-
phils may be beneficial and provides further support for the
development of drugs able to enhance neutrophil apoptosis,
increase elimination by macrophages and limit the damage
caused by prolonged activation of these cells.
Other diseases that may benefit from therapies targeting
neutrophil apoptosis are various types of non-infectious hu-
man arthritis such as rheumatoid arthritis, where the pres-
ence of neutrophils is deleterious. Importantly, neutrophils
are present in the acute phase of these diseases and are be-
lieved to play a significant role in tissue damage through
the release of toxic products such as oxidants, proteinases
and cytokines [53–55]. The presence of neutrophils per-
petuates the inflammatory process and enhances tissue de-
gradation and destruction, leading to disability and eventu-
al surgical joint replacement. In line with this idea, neutro-
phils isolated from the synovial fluids of arthritis patients
display increased survival compared to control [54]. Given
the aforementioned ability of neutrophils to modulate the
inflammatory process and immune responses, it is possible
that modulating neutrophil survival and apoptosis in arth-
ritis may present an exciting therapeutic target for reducing
joint inflammation and damage [56]. Preliminary studies
exploring the use of apoptotic cells in the treatment of arth-
ritis has found that mice injected with apoptotic cells pri-
or to the onset of collagen-induced arthritis were protec-
ted from severe joint inflammation and bone destruction
[57]. This protection appears to be the result of macrophage
reprogramming towards an anti-inflammatory and pro-
resolving state and subsequent modulation of other import-
ant cells including T and B lymphocytes, which also act to
secrete pro-resolving factors, promote tolerance and inhibit
chronic inflammation [58].
Conclusion
As our understanding of inflammation increases, there is
evidence to suggest that chronic inflammatory diseases in-
volve a functional defect in the resolution of inflammation,
which may act to maintain activation of the immune sys-
tem. There is strong evidence to suggest that neutrophils,
their apoptosis and subsequent elimination are able to act
as a strong pro-resolving force [24]. By understanding how
neutrophils live and the mechanisms that control their
death, it may lead to highly effective therapies for the treat-
ment of non-resolving and chronic inflammatory diseases.
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Figures (large format)
Figure 1
A summary of the function of neutrophils during immune responses.
Review article: Medical intelligence Swiss Med Wkly. 2015;145:w14056
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 8 of 10
Figure 2
Proliferating cell nuclear antigen (PCNA) is localised to the cytosol of myeloid progenitors and possesses a proliferative capacity. During the late
phases of granulocytic differentiation, PCNA is exported from the nucleus and become exclusively cytosolic. In mature neutrophils, PCNA
controls neutrophil survival through its interaction with other cytosolic proteins, such as procaspases, to prevent their activation. Upon apoptosis
induced by death signals or during the physiologic turnover of neutrophils and potentially following the modification of a partner protein, PCNA is
targeted to the proteasome to induce neutrophil death. As a result, cytosolic PCNA is considered to be a scaffolding protein capable of
controlling neutrophil survival.
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Figure 3
During sterile inflammation, neutrophils first adhere to the endothelium and undergo diapedesis. Following a gradient of chemotactic
compounds, they migrate to the site of inflammation and become activated, where they secrete oxidant and release proteinases. During the
normal progression of inflammation, neutrophils undergo apoptosis and express “eat-me-signals” which are recognised by macrophages. These
macrophages phagocytose the apoptotic neutrophils and are reprogrammed towards an anti-inflammatory and pro-resolving state. This figure
demonstrated the various steps in the neutrophil cycle, which may be targeted by an anti-inflammatory intervention.
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